Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 159.27M P/E - EPS this Y 23.90% Ern Qtrly Grth -
Income -32.12M Forward P/E -3.05 EPS next Y 50.80% 50D Avg Chg -17.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -30.00%
Dividend N/A Price/Book 7.30 EPS next 5Y - 52W High Chg -69.00%
Recommedations 2.00 Quick Ratio 2.55 Shares Outstanding 7.69M 52W Low Chg 143.00%
Insider Own 30.46% ROA -66.69% Shares Float 4.34M Beta -
Inst Own 6.01% ROE -208.26% Shares Shorted/Prior 139.76K/100K Price 4.39
Gross Margin - Profit Margin - Avg. Volume 243,537 Target Price 30.00
Oper. Margin - Earnings Date Nov 6 Volume 75,128 Change -3.09%
About BioVie Inc.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

BioVie Inc. News
11/20/24 BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
11/04/24 BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded
10/29/24 BioVie Inc. Announces Closing of Registered Direct Offering
10/28/24 UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
10/28/24 BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
10/24/24 BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement
10/23/24 BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
10/23/24 BioVie Announces Stock Offering and Private Placement
10/23/24 Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024
10/15/24 BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin
10/11/24 BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
10/01/24 BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin
09/25/24 BioVie Inc. Announces Closing of Public Offering
09/23/24 BioVie Inc. Announces Pricing of Public Offering
09/23/24 BioVie Inc. Announces Proposed Public Offering
09/16/24 BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID
09/03/24 BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID
08/27/24 BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting
08/13/24 BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting
08/08/24 BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease
BIVI Chatroom

User Image Tumble51 Posted - 7 hours ago

$BIVI Not with Cuong there

User Image mikejonesok Posted - 7 hours ago

$BIVI decent volume so far. Upside pop likely

User Image Thorilium Posted - 13 hours ago

$CYDY $BIVI - Both fully funded trials in 2025 - Both chosen for the fastest approval path - Drug safety 99% confirmed by research (CYDY+BIVI) or by the FDA (CYDY) - No financing issues - No share holders issues - No legal issues

User Image Soccerman0410 Posted - 19 hours ago

$BIVI 🚀🌙🌙🌙

User Image Dkll303 Posted - 1 day ago

$BIVI I think that is Justin Timberlake’s line …hahaha ..try another foolish comment @kkun

User Image Dkll303 Posted - 1 day ago

$BIVI Ya ..sure with Cuong and his lies ..doubt it ! Trials will once again be tainted

User Image Thorilium Posted - 1 day ago

$BIVI The planned Phase 2 study, which is fully funded by a grant from the U.S. Department of Defense (DOD), is a double-blind, randomized (1:1), placebo-controlled, multicenter trial in approximately 200 patients to evaluate the safety, tolerability and potential efficacy of 3 months of treatment with bezisterim to reduce the neurocognitive symptoms associated with Long COVID. 2 trials now ongoing both fully Funded .... https://feeds.issuerdirect.com/news-release.html?newsid=6945807073330360

User Image Thorilium Posted - 1 day ago

$BIVI the longer this stays below 4 the more I believe this will shoot first upwards towards 5 to come down in the high 4 range I see this company adding indications and the SP does not move?

User Image kkun Posted - 1 day ago

$BIVI who is ready for the next leg up? I have a feeling we see $4 today

User Image Thorilium Posted - 1 day ago

$BIVI extra non dillutive funding and this goes down? Go away 😆😆😆 Anyway the more this is kept down the harder this Will explode

User Image Thorilium Posted - 1 day ago

$BIVI suddenly all start to understand how close we were towards approval and understand the frustration of the CEO with a market cap that plunged 95%

User Image Luvtoretire Posted - 1 day ago

$BIVI

User Image HorsePicks Posted - 1 day ago

$BIVI BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

User Image Thorilium Posted - 1 day ago

$BIVI shorts are trapped in this one, huge short interest Short Interest % Float 35.56 % - source: NASDAQ (short interest), Capital IQ (float) and there is nothing to defend their short interest, so they are very fast under fire...huge swings potential

User Image Dkll303 Posted - 1 day ago

$BIVI you mean 40 СENTS ???? Hahaha ….looking at another dilution I see !

User Image Rexxar317 Posted - 1 day ago

$BIVI thought it was going 4s yesterday

User Image Stockwolfie Posted - 2 days ago

$ALGS is this the next $DRUG ? We got the shorts in today and have been stabilizing let’s get an attack in $BIVI $GME $HOLO

User Image _www_larval_com_ Posted - 2 days ago

$BIVI has soared 4% higher to 12% (~3Mv) in the last few minutes, 01/17 options, follow for more volatility.

User Image tanku2much Posted - 2 days ago

$BIVI 24K buy?! whata bounce back

User Image BradenGreen1 Posted - 2 days ago

$BIVI please keep shorting shorts. Only gonna make it pop higher and make me more money lol

User Image Nedwin513 Posted - 2 days ago

$BIVI ONE fantastic gorgeous chart.

User Image tanku2much Posted - 2 days ago

$BIVI could touch off a squeeze here, or not.

User Image PatrickTrades2 Posted - 2 days ago

$BIVI $2.39 adds paying huge. Trimming a bit around these levels, but still holding a large position. Fills in the $2.50s yesterday looking nice on $LMFA and should be back above $3 soon.

User Image Luvtoretire Posted - 2 days ago

$BIVI —📈

User Image Bullish_Swagger Posted - 2 days ago

$BIVI - Over $3.84 resistance area and increasing volume... Ready n waiting

User Image chris57 Posted - 2 days ago

$BIVI 🍌🍌🍌🍌🍌

User Image HoHoHoHum Posted - 2 days ago

$BIVI I see this gap filling to 4.3. Could happen quickly.

User Image Thorilium Posted - 2 days ago

$CYDY up 1.7 % market cap below 150 million - 14 indications - fully funded trial / drug safety (confirmed save by FDA) $BIVI up 6.75% market cap below 57 million - 3 indications / drug safety (confirmed save by trial results) understand that if BIVI doubles in SP the value is still below that of CYDY (also a pre-revenu company) so I would consider BIVI is valued very conservative today considering the ongoing trial (2025 - fully funded) and potential in high yielding drugs because older people have more money to stay healthy and Alzheimer and Parkinson are two terrible disease to suffer from not only for yourself but also for your family...

User Image kkun Posted - 2 days ago

$BIVI all clear now. No stops till 4.50 now IMO. Break of 4.50 could see 7

User Image Nedwin513 Posted - 2 days ago

$BIVI From 2.95, do it again

Analyst Ratings
ThinkEquity Buy Jul 1, 24
Oppenheimer Outperform Nov 30, 23
Cantor Fitzgerald Overweight Aug 22, 23
Cantor Fitzgerald Overweight Jul 18, 23
Cantor Fitzgerald Overweight May 17, 23
Oppenheimer Outperform May 17, 23
Oppenheimer Outperform Feb 14, 23
EF Hutton Buy Sep 28, 22
Cantor Fitzgerald Overweight Jul 22, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
DO CUONG V President & CEO President & CEO Nov 30 Buy 1.78 10,000 17,800 68,759 12/01/23
GORLIN STEVE Director Director Sep 05 Sell 3.05 8,560 26,108 75,680 09/07/23
BERMAN RICHARD J Director Director Aug 22 Sell 3.5009 10,805 37,827 16,789 08/24/23
BERMAN RICHARD J Director Director May 22 Sell 6.16 10,984 67,661 23,210 06/15/23
BERMAN RICHARD J Director Director Mar 27 Sell 8.52 10,984 93,584 34,194 04/06/23